New eczema drug tested in teens: safe or not?
NCT ID NCT07329101
First seen Jan 11, 2026 · Last updated May 06, 2026 · Updated 17 times
Summary
This early-stage study tested a new drug called VC005 in 11 teenagers aged 12-18 with mild to moderate atopic dermatitis (eczema). The main goal was to check safety and how the drug moves through the body. It was a small, open-label study with no comparison group, so it only gives initial safety data, not proof of effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (AD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hangzhou First People's Hospital
Hangzhou, Zhejiang, China
Conditions
Explore the condition pages connected to this study.